Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties with a Hold Rating
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...
AMD, Pinterest, and 6 Other Growth Stocks That Look Undervalued
Growth stocks are getting hammered by soaring bond yields. First off, long-dated bond yields have taken a wrecking ball to ...
MarketWatch11h
Exxon Mobil Corp.
Petroleo Brasileiro S/A Ord 0.49% R$504.45B Petroleo Brasileiro S/A Pref 0.27% R$504.45B ...
BioPharma Dive14h
Lilly blames slower-than-expected growth for 2024 sales miss
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...